Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10578939		
Art Unit		2007-02-14		
		Sinkel et al.		
		1645		
		Navarro		
		10030-003US1		

Examiner Initial* Cite No Patent Number				Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6312944		2001-11-06	Russell et al.	
	2	6565856		2003-05-20	Skeiky et al.	
	3	7384775		2008-06-10	Zagursky et al.	
	4	7635487		2009-12-22	Meinke et al.	
If you wisl	h to add	additional U.S. Pater	t citatio	n information pl	ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*		Cite No Publication Number		Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050020813		2005-01-27	Masignani et al.	
	2	20060264378		2009-09-29	Fujiietal.	

U.S. PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

20080085277

Application Number		10578939	
Filing Date		2007-02-14	
First Named Inventor	Van 0	Sinkel et al.	
Art Unit		1645	
Examiner Name	Mark Navarro		
Manager Davids Number		10020 0021191	

	4		20110130300		2011-06	3-02	Ochs-Onolem	hemhen et al.			
If you wis	h to a	dd ac	Iditional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Add	butt	on. Add	_
					FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	aminer Cite Foreign Document Code <sup>2</sup> i Code <sup>2</sup> Date Name of Patenlee or Applicant of cited Document				or	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TA				
	1										
If you wis	h to a	dd ac	Iditional Foreign Pa	atent Do	cument	citation	information p	lease click the Add	butto	n Add	
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	niner Cite lincude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), no						Τs				
	Sanchez-Beato et al., "Molecular characterization of PCPA: a novel distrine-binding protein of streptococcus pneumonae," FEMS Micro. Letters 164:207-214 (1998).										
	2 Yesikiya et al., "Identification of amno acids essential for catalytic activity of pneumococcal neutraminidase A" Research in Microbiology 157-569-574 (2006).										
If you wis	h to ac	dd ac	ditional non-paten	t literatu	re docu	ment cit	ation informat	ion please click the	Add	button Add	_
					EX	AMINE	R SIGNATUR	E			
Examiner	Signa	ature						Date Conside	red		
								ormance with MPE		Draw line through a     to applicant	

2008-04-10 Cho et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10578939	
	Filing Date		2007-02-14	
	First Named Inventor Van 0		Ginkel et al.	
	Art Unit		1645	
	Examiner Name Mark		Navarro	
	Attorney Docket Numb	er	10030-003US1	

See First Codes of USPTO Planto Documents at view, USPTO, DOV or MPEP D01.04. \* Exter difficie that issued the document, by the two before code (VIPO) Standard ST3.3.\* \* Explaneses paint documents, the includation of the paint of the improve must preced the senial number of the paint document of the paint of the pai

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10578939		
Filing Date		2007-02-14		
First Named Inventor	Van Ginkel et al.			
Art Unit		1645		
Examiner Name	Mark	Mark Navarro		
Attorney Docket Number		10030-003US1		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make the	appropriate selection(s)
---------------	----------	----------------------	--------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e/t1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew Baraniak/	Date (YYYY-MM-DD)	2011-11-02
Name/Print	Andrew Baraniak	Registration Number	65 945

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiler. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public fifthe record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.